WorldPingA Novartis drug for a rare neuromuscular condition failed in a key study, the company's second major trial collapse in a matter of days.
This is a short WorldPing brief. The full report was published by STAT.
Read the full report at STATMore coverage: all health news on WorldPing.
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Brief by WorldPing · Original reporting by CNBC World
WorldPingBitcoin, gold and technology stocks fall as the yen rallies, while oil prices and government bond yields climb globally.
Brief by WorldPing · Original reporting by CoinDesk
WorldPingGerman Chancellor Friedrich Merz has doubled down on pushing through unpopular reforms to Europe’s largest economy after a far-right party surged to a landslide victory in a regional election, with a very good chance of forming the first far-right stat...
Brief by WorldPing · Original reporting by ABC News
WorldPingA man died after consuming poison following alleged pressure from local leaders. He had questioned Punjab Finance Minister Harpal Singh Cheema about synthetic drug supply. His family claims he was pressured to apologize for raising the issue publicly.
Brief by WorldPing · Original reporting by Times of India
Eric Wu, who built and ran Opendoor before stepping away in 2022, has had his new company, NavigateAI, out of stealth since May — building AI copilots that give construction workers real-time, hands-free guidance through smartphones and Meta's AI gla…
Brief by WorldPing · Original reporting by TechCrunch
WorldPingCrime levels are falling for most offenses across the UK—but the public doesn't necessarily feel safer.
Brief by WorldPing · Original reporting by Phys.org
WorldPing